AMRA has entered into an exclusive agreement with the imaging CRO (Contract Research Organization) in Japan, Micron, to guide and support pharmaceutical and research clients in Japan with clinical trials.
“We are very happy to have Micron as a partner for the second largest medical market. A local partner in the sophisticated Japanese market is necessary and will mean better service to domestic clients,” says Eric Converse, CEO of AMRA.
Strengthen our relationships in Japan
Combining AMRA’s MRI Body Composition Profiling, expertise in metabolic diseases, musculoskeletal conditions and muscle wasting, with Micron’s existing penetration into the Japanese imaging research markets, will mean growth for both companies. Micron, having Japan’s largest medical imaging analysis team, has the logistical organization and know-how to support launching AMRA’s technology in Japanese clinical trials, states the company.
“Japanese pharmaceutical companies and academic researchers show great interest in AMRA’s digital health solutions and with this partnership we can expect increased business and strengthen our relationships in Japan,” says Rosemary Shull, Senior Vice President, Global Business Development & Marketing of AMRA.
Photo of Eric Converse: AMRA